| 李 研,张艳丽,孙瑞坦,罗斯文,丁 红,朴翔宇.叶酸、甲钴胺对脑血管病患者同型半胱氨酸水平及认知障碍疗效观察[J].现代生物医学进展英文版,2017,17(17):3299-3301. |
| 叶酸、甲钴胺对脑血管病患者同型半胱氨酸水平及认知障碍疗效观察 |
| Observation on the Effects of Folic Acid and Mecobalamin on Homocysteine Levels and Cognitive Impairment of Patients with Cerebrovascular Disease |
| Received:August 30, 2016 Revised:September 25, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.17.024 |
| 中文关键词: 脑血管病 叶酸 甲钴胺 认知障碍 同型半胱氨酸 |
| 英文关键词: Cerebrovascular disease Folic acid Mecobalamin Cognitive impairment Homocysteine |
| 基金项目:辽宁省科技厅科学技术计划项目（2012225021） |
|
| Hits: 446 |
| Download times: 209 |
| 中文摘要: |
| 摘要 目的：探讨叶酸、甲钴胺对脑血管病患者血清同型半胱氨酸水平、以及认知障碍的疗效。方法：112例脑血管病患者，用随机表法，将患者分为三个叶酸组、甲钴胺组和联合治疗(叶酸+甲钴胺)组。叶酸组口服叶酸5 mg(1次/天)。甲钴胺组予以甲钴胺口服500 μg(3次/天)。联合治疗组联合用药，连续口服6个月。评价治疗前后的血清同型半胱氨酸及认知障碍评分。结果：治疗后，三组间血清同型半胱氨酸水平差异有统计学意义(P<0.05)。联合治疗组血清同型半胱氨酸水平明显低于叶酸组和甲钴胺组(P<0.05)。三组间认知障碍MMSE评分差异有统计学意义(P<0.05)。甲钴胺组和联合治疗组治疗前后MMSE评分差异有统计意义(P<0.05)，但叶酸组治疗前后MMSE评分差异无统计学意义(P>0.05)。联合治疗组认知障碍MMSE评分水平水平明显高于叶酸组和甲钴胺组(P<0.05)。结论：叶酸联合甲钴胺能够改善脑血管病患者认知障碍评分，降低血清同型半胱氨酸水平，但叶酸对认知障碍无明显疗效。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative effects of folic acid, mecobalamin on serum homocysteine levels and cognitive im- pairment of cerebrovascular patients. Methods: A total of 112 patients with cerebrovascular disease in our hospital were randomly divided into three groups, namely, folic acid group, mecobalamin group and combination group (folic acid + mecobalamin). Patients in folic acid group had oral folic acid 5 mg once per day. Patients in mecobalamin group had mecobalamine orally 500 μg (3 times/day). Patients in combination group had the combination of two. All had treatment for 6 consecutive months. The evaluation on serum homocysteine lev- els and cognitive impairment scores were carried out before and after treatment. Results: After treatment, the serum homocysteine levels had significant differences between the three groups (P<0.05). The serum homocysteine levels in combination group were significantly lower than in the folic acid group and mecobalamin group (P<0.05). The cognitive impairment MMSE score also showed statistically sig- nificant difference between three groups (P<0.05). The MMSE score had statistical differences between before and after treatment in mecobalamin group and combination group (P<0.05), but no statistical difference in MMSE score was found between before and after treatment in folic acid group (P>0.05). The cognitive impairment MMSE score in combination group was obviously higher than in folic acid group and mecobalamin group (P<0.05). Conclusion: Folic acid combined with mecobalamin can reduce serum homocysteine levels, and improve cognitive impairment score in patients with cerebrovascular disease. But folic acid had no obvious curative effects on cogni- tive impairment. |
|
View Full Text
View/Add Comment Download reader |
| Close |
